A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy
暂无分享,去创建一个
Gordon Mills | Yoo-Shin Kim | Woo-Young Kim | G. Mills | W. Hong | B. Hennessy | Hyun-Ju Park | Ho-Yyoung Lee | Woo-Young Kim | Kyu-Won Kim | Jakyung Yoo | Y. Suh | Ho-Young Lee | Dong Jo Chang | Bryan Hennessy | Hae Jin Kang | Jakyung Yoo | Seung-Ho Han | Hyun-Ju Park | Seung-Yong Geo | Kyu-Won Kim | Waun Ki Hong | Young-Ger Suh | Yoo-shin Kim | Dong-Jo Chang | Seungryel Han | Seung-Yong Geo | W. Hong
[1] J. Pezzuto,et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. , 1997, Cancer research.
[2] W. Hong,et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. , 2007, Cancer research.
[3] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[4] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[5] Tetsuya Takahashi,et al. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of α‐synuclein via Src‐family kinases , 2002 .
[6] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Y. Fujita,et al. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. , 2005, Journal of pharmacological sciences.
[8] J. Pezzuto,et al. Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. , 1997, Cancer research.
[9] J. Pezzuto,et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase , 1995, Nature Medicine.
[10] R. Clark,et al. Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.
[11] C. Bevan,et al. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.
[12] L. Tretter,et al. Initiation of Neuronal Damage by Complex I Deficiency and Oxidative Stress in Parkinson's Disease , 2004, Neurochemical Research.
[13] W. Hong,et al. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia‐inducible factor‐1 alpha , 2008, International journal of cancer.
[14] Sheila M. Thomas,et al. Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.
[15] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[16] H. Varmus,et al. Detection and enumeration of transformation-defective strains of avian sarcoma virus with molecular hybridization. , 1977, Virology.
[17] S. Courtneidge,et al. The interplay between Src family kinases and receptor tyrosine kinases , 2004, Oncogene.
[18] Jing He,et al. Deguelin regulates nuclear pore complex proteins Nup98 and Nup88 in U937 cells in vitro , 2005, Acta Pharmacologica Sinica.
[19] P. Gargalovic,et al. Cellular apoptosis is associated with increased caveolin-1 expression in macrophages Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M300140-JLR200 , 2003, Journal of Lipid Research.
[20] K. Ono,et al. A src family tyrosine kinase inhibits neurotransmitter release from neuronal cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] R. Price,et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. , 2005, Journal of the National Cancer Institute.
[22] B. Lu,et al. Inducers of oxidative stress block ciliary neurotrophic factor activation of Jak/STAT signaling in neurons , 2005, Journal of neurochemistry.
[23] R. Nussbaum,et al. α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases* , 2001, The Journal of Biological Chemistry.
[24] Pierluigi Caboni,et al. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. , 2004, Chemical research in toxicology.
[25] J. Minna,et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.
[26] Xuming He,et al. Non-parametric quantification of protein lysate arrays , 2007, Bioinform..
[27] E. Zuhowski,et al. Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers , 2005, Clinical Cancer Research.
[28] V. Tantishaiyakul. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modeling. , 2004, International journal of pharmaceutics.
[29] N. Rosen,et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. , 1999, Cancer research.
[30] G. Ramponi,et al. c-Src activates both STAT1 and STAT3 in PDGF-stimulated NIH3T3 cells. , 1997, Biochemical and biophysical research communications.
[31] G. Cordell,et al. Identification of Degradation Product of Deguelin and Its Stability Using Liquid Chromatography and Electrospray/Mass Spectrometry , 2004 .
[32] S. Hecht. Deguelin as a chemopreventive agent in mouse lung tumorigenesis induced by tobacco smoke carcinogens. , 2005, Journal of the National Cancer Institute.
[33] J. Trevino,et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes , 2005, Molecular Cancer Therapeutics.
[34] Y. Lazebnik,et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.
[35] Takeshi Nakamura,et al. Identification and Characterization of a Novel Pyk2/Related Adhesion Focal Tyrosine Kinase-associated Protein That Inhibits α-Synuclein Phosphorylation* , 2003, Journal of Biological Chemistry.
[36] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[37] L. Grochow,et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Jove,et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.
[39] Lin Ji,et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. , 2004, Journal of the National Cancer Institute.
[40] R. Lotan,et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. , 2003, Journal of the National Cancer Institute.
[41] E. Clark. A RELATION BETWEEN ROTENONE, DEGUELIN AND TEPHROSIN. , 1931, Science.
[42] K. Manton,et al. ROS effects on neurodegeneration in Alzheimer's disease and related disorders: on environmental stresses of ionizing radiation. , 2004, Current Alzheimer research.
[43] W. Hong,et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. , 2007, Journal of the National Cancer Institute.
[44] K. Fizazi,et al. The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] Ho-Yyoung Lee. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. , 2004, Biochemical pharmacology.
[46] Tetsuya Takahashi,et al. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. , 2001, Biochemical and biophysical research communications.